Innovation – planned indications
Chronic hepatitis B
Chronic Hepatitis B is a potentially life-threatening liver infection caused by the HBV. Worldwide, an estimated two billion people were HBV infected, whereas more than 350 million of those have chronic liver infections. Chronic hepatitis B is a serious global public health issue. Up to 1.2 million deaths per year are caused by HBV-related chronic liver diseases resulting in it being the 10th leading cause of death worldwide. Without appropriate treatment, 15-25% of the chronically infected will die prematurely, because of the severe and fatal complications of chronic liver disease.
In addition to hepatitis, Bulevirtide has a potential for the treatment of a variety of inflammatory and metabolic diseases via additional pharmacological effects of NTCP inhibition. MYR Pharma and its collaborators have obtained encouraging preclinical data that support further development of Bulevirtide to treat dyslipidemia, nonalcoholic steatohepatitis (NASH), and primary biliary cholangitis (PBC).